<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR67">
 <label>67.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Richardson</surname>
    <given-names>PG</given-names>
   </name>
   <name>
    <surname>Attal</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Campana</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Le-Guennec</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Hui</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Risse</surname>
    <given-names>ML</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design</article-title>
  <source>Future Oncol</source>
  <year>2018</year>
  <volume>14</volume>
  <fpage>1035</fpage>
  <lpage>1047</lpage>
  <pub-id pub-id-type="doi">10.2217/fon-2017-0616</pub-id>
  <?supplied-pmid 29268619?>
  <pub-id pub-id-type="pmid">29268619</pub-id>
 </element-citation>
</ref>
